Compare FRPH & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRPH | SLDB |
|---|---|---|
| Founded | 1986 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 435.3M | 444.9M |
| IPO Year | N/A | 2018 |
| Metric | FRPH | SLDB |
|---|---|---|
| Price | $23.86 | $6.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $14.70 |
| AVG Volume (30 Days) | 60.8K | ★ 950.8K |
| Earning Date | 03-04-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $33,049,999.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $97.90 | ★ N/A |
| Revenue Growth | ★ 5.21 | N/A |
| 52 Week Low | $21.68 | $2.41 |
| 52 Week High | $31.99 | $7.37 |
| Indicator | FRPH | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 54.66 | 69.49 |
| Support Level | $23.42 | $5.26 |
| Resistance Level | $24.62 | $5.96 |
| Average True Range (ATR) | 0.53 | 0.41 |
| MACD | 0.07 | 0.10 |
| Stochastic Oscillator | 61.14 | 96.25 |
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, warehouse, and office buildings either alone or through joint ventures (the Development Segment); ownership, leasing and management of buildings through joint ventures (the Multifamily Segment).
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.